BIOYF / RX.V is a potential multi-bagger home run IMO. Here's why:
(1) BIOYF / RX.V is debt-free, cash-rich making money hand over fist compared to its tiny market cap and growing rapidly. Their key product, Feramax, is getting rave reviews by pharmacists, doctors, and users.
(2) Last quarter they had +.025 EPS (w/o one-timers of .006). Annualized + growth makes them appear very cheap to me especially vs. future increased potential EPS.
(3) Their pharmaceutical sales division has shown on average +40% sequential growth in sales each quarter for many quaters so far. Over +215% year-over-year growth last quarter with massive gross profitability margins (78.6% company-wide last quarter)
(4) I'm thinking RX.V / BIOYF will launch 2 new products this year, and each year after for a while based on my research so there is a wild card that any one or more of these additional products can be home runs as well.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.